Anaerobic protozoa and bacteria

Anaerobic protozoa and bacteria constitute a diverse group of microorganisms that thrive in environments with low oxygen tension, such as the human gastrointestinal and genitourinary tracts (Merck Manual, 2023). This category encompasses various pathogenic protozoa, including Giardia lamblia and Entamoeba histolytica, as well as anaerobic bacteria like Bacteroides fragilis and Clostridioides difficile (CDC, 2022). These organisms are characterized by their reliance on anaerobic metabolic pathways, such as fermentation, which distinguish them from aerobic species. In clinical pharmacology, they are the primary targets of nitroimidazole antibiotics like metronidazole, which act as prodrugs (StatPearls, 2023). These drugs undergo reductive activation specifically within the anaerobic environment of the target cells, generating reactive oxygen species and free radicals that cause DNA damage and inhibit nucleic acid synthesis. Because this entry refers to a broad taxonomic grouping of pathogens rather than a specific protein, enzyme, or receptor, it does not qualify as a discrete molecular target.

Other names

Anaerobic microorganismsAnaerobesAnaerobic pathogens

Nitroimidazole drugs are prodrugs that require reductive activation of the nitro group by electron transport proteins like ferredoxin found in anaerobic metabolism, leading to the formation of reactive cytotoxic intermediates that damage DNA (StatPearls, 2023).